Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
87,69 EUR | -0,95 % | -1,82 % | -2,28 % |
Kurzporträt
- Pharmazeutische Produkte (70,6%): verschreibungspflichtige Arzneimittel in den Bereichen Spezialmedizin (59,3% des Nettoumsatzes; zur Behandlung von Multipler Sklerose, neurologischen Erkrankungen, Entzündungskrankheiten, Autoimmunerkrankungen, seltenen Erkrankungen, Krebs und seltenen hämatologischen Erkrankungen) und Allgemeinmedizin (40,7%; hauptsächlich zur Behandlung von Diabetes und Herz-Kreislauf-Erkrankungen);
- Humanimpfstoffe (17,4%): pädiatrische Impfstoffe, Impfstoffe gegen Grippe, Meningitis und Polio, Auffrischungsimpfstoffe und Impfstoffe für Reisende und endemische Gebiete;
- Gesundheitsprodukte für Verbraucher (12%).
Ende 2023 verfügte der Konzern über 54 Produktionsstandorte in der ganzen Welt.
Der Nettoumsatz verteilt sich geographisch wie folgt: Frankreich (5,5%), Europa (18,6%), die Vereinigten Staaten (43%), Nordamerika (1,6%) und andere (31,3%).
Mitarbeiterzahl: 86 088
Umsatz nach Geschäftsbereich
EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Biopharma
88,0
%
| 30 688 | 71,4 % | 37 890 | 88,0 % | +23,47 % |
Consumer Healthcare
12,0
%
| 5 080 | 11,8 % | 5 180 | 12,0 % | +1,97 % |
Umsatz je Region
EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
43,0
%
| 18 275 | 42,5 % | 18 512 | 43,0 % | +1,30 % |
Rest of the World
26,1
%
| 8 386 | 19,5 % | 11 254 | 26,1 % | +34,20 % |
Europe
18,6
%
| 7 703 | 17,9 % | 8 013 | 18,6 % | +4,02 % |
China
6,8
%
| 3 123 | 7,3 % | 2 912 | 6,8 % | -6,76 % |
France
5,5
%
| 2 296 | 5,3 % | 2 379 | 5,5 % | +3,61 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 01.09.19 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 01.01.22 |
Chief Tech/Sci/R&D Officer | 51 | - | |
Nestle Frank
CTO | Chief Tech/Sci/R&D Officer | - | 01.09.16 |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 49 | 11.09.23 |
Dietmar Berger
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.19 |
Arnaud Delépine
IRO | Public Communications Contact | - | - |
Raj Verma
PRN | Corporate Officer/Principal | - | 01.12.20 |
- | - | ||
Corporate Officer/Principal | 62 | 01.01.15 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 01.05.14 |
Lise Kingo
BRD | Director/Board Member | 62 | 28.04.20 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 22.05.20 |
Frédéric Oudéa
CHM | Chairman | 60 | 02.09.22 |
Rachel Duan
BRD | Director/Board Member | 52 | 28.04.20 |
Antoine Yver
BRD | Director/Board Member | 66 | 03.05.22 |
Carole Ferrand
BRD | Director/Board Member | 53 | 03.05.22 |
Paul Hudson
CEO | Chief Executive Officer | 56 | 01.09.19 |
Director/Board Member | 58 | 30.04.19 | |
Emile Voest
BRD | Director/Board Member | 64 | 03.05.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 1 264 799 969 | 1 102 029 493 ( 87,13 %) | 13 450 388 ( 1,063 %) | 87,13 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
SANOFI 1,28% | 16 245 648 | 1,28% | 1 583 032 151 $ |
SANOFI INDIA LIMITED 60,40% | 13 909 587 | 60,40% | 1 439 304 947 $ |
EUROAPI 29,77% | 28 298 074 | 29,77% | 110 900 718 $ |
MEIRAGTX HOLDINGS PLC 7,31% | 4 697 737 | 7,31% | 23 018 911 $ |
MEIRAGTX HOLDINGS PLC 8,00% | 1 157 926 | 8,00% | 18 816 298 $ |
LAVA THERAPEUTICS N.V. 7,30% | 1 919 455 | 7,30% | 4 337 968 $ |
ENENTO GROUP OYJ 0,12% | 29 249 | 0,12% | 575 359 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Chattem, Inc.
Chattem, Inc. Pharmaceuticals: MajorHealth Technology Chattem, Inc. engages in the manufacture of over-the-counter health and beauty care products. It makes anti-dandruff shampoos, medicated skin care, topical pain care, oral care and internal over-the-counter products. The firm distributes its products to mass merchandisers, drugstores and food retail channels. The company was founded by Zeboim Cartter Patten on February 21, 1879 and is headquartered in Bridgewater, NJ. |
Pharmaceuticals: Major
|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. |
Medical Specialties
|
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Aventis, Inc.
| |
Sanofi-Synthélabo Ltd.
Sanofi-Synthélabo Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Synthélabo Ltd. is a pharmaceutical company based in Reading, UK. The British company was founded in 1990 and specializes in manufacturing and distributing solid-dose and pharmaceutical products. |
Pharmaceuticals: Major
|
Sanofi Pasteur, Inc.
Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. |
Pharmaceuticals: Major
|
Sanofi-aventis Ireland Ltd.
Sanofi-aventis Ireland Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-aventis Ireland Ltd. manufactures pharmaceutical products for cardiovascular, central nervous system, metabolic disorders, cardiometabolic, oncology, thrombosis, and vaccines. The company is headquartered in Dublin, Ireland. |
Pharmaceuticals: Major
|
Sanofi-Aventis Europe SAS
Sanofi-Aventis Europe SAS Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Aventis Europe SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the company is Jérôme Contamine. |
Pharmaceuticals: Major
|
Genzyme Therapeutic Products LP
Genzyme Therapeutic Products LP BiotechnologyHealth Technology Part of Sanofi, Genzyme Therapeutic Products LP is a company that specializes in biological products except diagnostic substances. The company is based in Boston, MA. |
Biotechnology
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+52,93 % | 803 Mrd. | |
+40,98 % | 629 Mrd. | |
-7,08 % | 351 Mrd. | |
+17,40 % | 324 Mrd. | |
+10,58 % | 303 Mrd. | |
+16,42 % | 244 Mrd. | |
+2,17 % | 226 Mrd. | |
+10,66 % | 215 Mrd. | |
+6,24 % | 164 Mrd. |
- Börse
- Aktien
- 920657 Aktie
- 920657 Aktie
- Unternehmen Sanofi